Clinical Trial

Investigation of Individualised Antisense Oligonucleotides (ASOs) in People With Unique Genetic Variants Causing Severely Debilitating, Life Threatening (SDLT) Central Nervous System (CNS) Conditions

Study acronym: EOM-MP1
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is being conducted to evaluate individualised antisense oligonucleotides (ASOs) in participants with severely debilitating, life threatening (SDLT) central nervous system (CNS) conditions caused by unique genetic variants amenable to correction by an ASO.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-02-07; most recent amendment 2026-03-16.
Status change: Enrolling by Invitation → Active, Not Recruiting 2026-03-16
Trial Details
NCT Number NCT07410143
Lead Sponsor EveryONE Medicines Inc.
Conditions Pediatric SDLT CNS Disorders
Enrollment 1 participants
Start Date 2026-01-13
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-17